Anti-Cisplatin modified DNA抗体[CP9/19] (ab103261)

概述

  • 产品名称
    Anti-Cisplatin modified DNA抗体[CP9/19]
  • 描述
    大鼠单克隆抗体[CP9/19] to Cisplatin modified DNA
  • 经测试应用
    适用于: ELISA, Flow Cyt, Dot blotmore details
  • 种属反应性
    与反应: Human
  • 免疫原

    Cisplatin Modified Native DNA.

  • 阳性对照
    • RNA/DNA.
  • 常规说明


    This antibody enables the quantification of cisplatin-induced adducts on DNA. It has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines.

性能

  • 形式
    Liquid
  • 存放说明
    Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
  • 存储溶液
    Preservative: None
    Constituents: PBS
  • Concentration information loading...
  • 纯度
    Immunogen affinity purified
  • Primary antibody说明
    This antibody enables the quantification of cisplatin-induced adducts on DNA. It has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines.
  • 克隆
    单克隆
  • 克隆编号
    CP9/19
  • 骨髓瘤
    Y3/Ag1.2.3
  • 同种型
    IgG2a
  • 研究领域

应用

Our Abpromise guarantee covers the use of ab103261 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
ELISA Use at an assay dependent concentration.
Flow Cyt Use at an assay dependent concentration. PubMed: 23370278

ab18450 - Rat IgG2a kappa monoclonal, is suitable for use as an isotype control with this antibody.

Dot blot Use at an assay dependent concentration. PubMed: 25356874

Anti-Cisplatin modified DNA antibody [CP9/19] 图像

  • ab103261 staining Cisplatin modified DNA in human ovarian cancer cell line A2780 by Flow Cytometry. Cells in culture were detached by accutase treatment, fixed with 70% ehtanol for 30 min at 4°C and permeabilized with 100ug/ml digitonin in PBS. The sample was incubated with the primary antibody (1/200 in PBS + 1% FBS) for 18 hours at 4°C. A FITC-conjugated rabbit anti-rat IgG H&L polyclonal (1/200) was used as the secondary antibody. Gating Strategy: FITC positive cells.

    The sh2 represents the gene knock down cell line which showed positive staining with anti-cisplatin adduct antibody upon cisplatin treatment, whereas the control cells (cis-R, resistant to cisplatin) did not show any staining with anti-cis adduct antibody upon cisplatin treatment.

    See Abreview

Anti-Cisplatin modified DNA antibody [CP9/19] (ab103261)参考文献

This product has been referenced in:
  • Hu J  et al. Cisplatin DNA damage and repair maps of the human genome at single-nucleotide resolution. Proc Natl Acad Sci U S A 113:11507-11512 (2016). Read more (PubMed: 27688757) »
  • Rocha CR  et al. Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. Cell Death Dis 5:e1505 (2014). Dot blot, ICC/IF ; Human . Read more (PubMed: 25356874) »

See all 5 Publications for this product

Product Wall

Application
Flow Cytometry
Sample
Human Cell (human ovarian cancer cell line A2780)
Permeabilization
Yes - 100ug/ml digitonin in PBS
Gating Strategy
FITC positive cells
Specification
human ovarian cancer cell line A2780
Preparation
Cell harvesting/tissue preparation method: Cells in culture detached by accutase treatment
Sample buffer: PBS
Fixation
70% ehtanol for 30 min at 4 degrees
Username

Abcam user community

Verified customer

提交于 Apr 16 2015

Application
Immunocytochemistry/ Immunofluorescence
Sample
Human Cell (ovarian cancer A2780 cell line)
Specification
ovarian cancer A2780 cell line
Permeabilization
Yes - 0.1% digitonin in PBS
Fixative
70% ethanol
Username

Abcam user community

Verified customer

提交于 Aug 25 2014

Regarding the question of whether ab103261 (Anti-Cisplatin modified DNA antibody [CP9/19]) recognizes adducts in chromatin or pure DNA, the antibody was raised against purified drug-modified DNA. For a number of reasons one would expect adducts on DNA ...

Read More

Thank you for your recent telephone enquiry and for your patience.

I apologize for the long delay in getting back to you. We have been waiting to receive further information from the originator of this antibody.

I am sorry to conf...

Read More

Thisantibody targets adducts present in polymeric DNA.


For any further information I would suggest the reference by Tilby et al. A pubmed link to this paper can be found under the 'Specific references' tab on the online product datashee...

Read More

Thank you very much for your interest in ab103261.

To our knowledge, ab103261 has not been tested in IHC and thereforewe do not have any protocol suggestions.

I can offer a discount off a future purchase if you buy ab103261 now, te...

Read More
Application
ELISA
Sample
Human Cell (melanoma)
Specification
melanoma
Blocking step
BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 0.74µg/mL · Temperature: 20°C
Type
Direct
Username

Abcam user community

Verified customer

提交于 May 04 2012

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

注册